DEADLINE: FHRI Innovation Seed Fund 2025-26 [extended]
2026-01-30 08:00 - 09:00 (Australia/Perth) | Apply online
The purpose of the Innovation Seed Fund 2025-26 is to support WA innovators to develop and commercialise their health and medical innovations through start-up companies operating in WA, creating high-value jobs and enhancing the biomedical support and manufacturing capacity of the State.
The funding will be used to support the validation of inventive concepts, the feasibility testing of proposed solutions, and the advancement of developed solutions towards the path of commercialisation within the following streams:
Stream 1 – Devices, diagnostic and digital
The innovation is a device or technology that will prevent, diagnose, treat and/or monitor a health condition that impacts the people of Western Australia. This includes but is not limited to novel equipment, digital tools, and medical implants that aim to improve the safety, effectiveness, access, timeliness and/or cost as compared with existing practice.
Stream 2 – Therapeutics and vaccines
The innovation is a drug, compound or medical biologic that will prevent, detect, or treat a health condition that impacts the people of Western Australia. This includes but is not limited to novel medicines, vaccines, immune modulators and other medical products derived from chemical or biological material that aim to improve safety, quality, access or patient outcomes as compared with existing practice.
Expression of Interest applications due: 1:00pm (AWST), Thursday 22 January 2026*
Extended to 30 Jan 2026

DEADLINE: AusBiotech Investor Readiness Panel (IRP) EOIs
2026-01-30 08:00 - 09:00
AusBiotech is proud to announce the establishment of its new Investor Readiness Panel (IRP).
The IRP will provide stage-appropriate, non-binding guidance on a company’s readiness to engage with investors.
Individuals with experience engaging life sciences companies across stages can apply, including:

Founders or CEOs of life sciences companies
Translational, clinical, or scientific experts
Commercialisation, licensing, or scale-up professionals
Investors (VC, CVC, family office, angel)

Successful applicants will demonstrate:

Ability to assess readiness to engage investors (not investment quality)
Comfort providing clear, written feedback asynchronously
Understanding (and able to help define) stage-appropriate investor engagement
Alignment with ’s non-endorsement, discovery-safe principles
Capacity to review submissions within agreed timeframes

Your contributions will be invaluable in shaping the direction and future investment progress that support the Australian ecosystem and AusBiotech.
